The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Decitabine Versus Supportive Care in Adults With Advanced-stage MDS
Official Title: A Randomized, Open-label, Phase III Trial of Decitabine (5-aza-2'Deoxycytidine) Versus Supportive Care in Adults With Advanced-stage Myelodysplastic Syndrome
Study ID: NCT00043381
Brief Summary: To compare the safety and efficacy profiles of decitabine to those of supportive care in adults with advanced-stage myelodysplastic syndrome (MDS)
Detailed Description: This experimental (investigational) study is intended to answer the question of whether decitabine is any better than supportive care alone in delaying progression (worsening) of the disease, prolonging survival or improving the overall quality of life for MDS patients who are not candidates for bone marrow transplant (BMT).
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Alta Bates Comprehensive Cancer Center, Berkeley, California, United States
City of Hope National Medical Center, Duarte, California, United States
Scripps Clinic, Escondido, California, United States
Loma Linda Univ. Cancer Center, Loma Linda, California, United States
Univ. California San Francisco Medical School, San Francisco, California, United States
University of Florida, Gainsville, Florida, United States
H. Lee Moffitt Cancer Center, Tampa, Florida, United States
James A. Haley Veteran's Hospital, Tampa, Florida, United States
Rush Medical Center, Chicago, Illinois, United States
University of Illinois at Chicago, Chicago, Illinois, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
New England Medical Center Hospital, Boston, Massachusetts, United States
University of Massachusetts Medical School, Worcester, Massachusetts, United States
VA Medical Center, Minneapolis, Minnesota, United States
Washington Univ. School of Medicine, St. Louis, Missouri, United States
Roswell Park Cancer Institute, Buffalo, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Mount Sinai Medical Center, New York, New York, United States
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
Duke University Medical Center, Durham, North Carolina, United States
The Memphis Cancer Center, Memphis, Tennessee, United States
SW Regional Cancer Center (dba Central Texas Oncology Associates), Austin, Texas, United States
Texas Oncology, Dallas, Texas, United States
MD Anderson Cancer Center, Houston, Texas, United States